
Clerk of the House of Representatives Legislative Resource Center B-106 Cannon Building Washington, D.C. 20515 Secretary of the Senate Office of Public Records 232 Hart Building Washington, D.C. 20510



99 AUG 16 PM 1: 14

LOBBYING REPORT

HANG DELIVERED []

Lobby Disclosure Act of 1995 (Section 5) — All Filers Are Required To Complete This Page

Registrant Nume			
iřogan & Hartson L.L.P.			
Address G Check if different than previously reported Columbia Square, 555 Thirteenth Street, N.W. Washington, D.C. 20004-1109			
Principal Place of Business (if different from line 2) City State()	Up (or Country)		
	E-mail (optional) 5. Senate ID # 18422-1611		
7. Client name II Self Pharmaceutical Research Manufacturers of America (PhRMA)	6. House ID # 30470157		
	anuary 1-June 30) S OR Year End (July 1-December 31)		
10. Check if this is a Termination Report □ □ Termination Date 11. No Lobbying Activity □			
INCOME OR EXPENSES — Complete Either Line			
12. Labbying Firms	13. Organizations		
INCOME relating to lobbying activities for this reporting period was:	EXPENSES relating to lobbying activities for this reporting period were:		
Less than \$10,000	Less than \$10,000 🔯		
\$10,000 or more \$ \$ \$ \$0,000 Income (newest \$20.040)	\$10,000 or more		
Provide a good faith estimate, rounded to the nearest \$20,000, of all lobbying related income from the client (including all payments to the registrant by any other entity for lubbying activities on behalf of the client).	14. REPORTING METHOD. Check box to indicate expense accounting method. See instructions for description of options.		
·	☐ Method A. Reporting amounts using LDA definitions only		
·	☐ Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code		
	Method C. Reporting amounts under section 162(e) of the Internal Revenue Code		
Signature W. M. Th	Date 3/3/57		
Printed Name and Title Watten H. Maruyama, Partner			
LD-1 (REV. 6/98)	PAGE 1 of 3		

Registrant Name Hogan & Hartson L.L.P.	Client Name	Pharmaceutical Research Manufactu of America (PhRMA)	rets
LOBBYING ACTIVITY. Select as many codes a engaged in lobbying on behalf of the client during t information as requested. Attach individual page(s)	he reporting period. Us		
15. General issue area code <u>TRD</u> (one per pa	ge)		
16. Specific lobbying issues Fast-track legislation; pharmaceutical trade, intellect De-Regulation Initiative	ual property rights, U.S.	-Japan Enhanceð	
17. House(s) of Congress and Federal agencies conts U.S. House of Representatives U.S. Senate Office of U.S. Trade Representative Department of Commerce Department of State NEC/NSC 18. Name of each individual who acted as a lobbyist		None	
Name	Covered Offic	ial Position (if applicable)	New
Jeanne S. Archibald	Partner		<u>o</u>
Warren H. Магиуатта	Partner		<u> </u>
			Q
			
			<u> </u>
	·		
19. Interest of each foreign entity in the specific issu Signature Printed Name and Title Warren H. Martyama Panner E.D-2 (REV. 6/98)	es listed on line 16 abov	e Ef Check if None	
· 爱宝			têu bus